The results of the present study suggest that HMGCLL1 blockade could potentially sensitize CML LSCs to TKI therapy and improve the DMR rate following this treatment. The gene discussed is HMGCLL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.